摘要
目的:探讨活血解毒方对糖尿病大鼠视网膜病变血管紧张素Ⅱ(angiotensinⅡ,AngⅡ)和内皮素-1(endothelin-1,ET-1)的影响。方法:采用链脲佐菌素(65 mg.kg-1)1次性ip的方法建立糖尿病大鼠模型,随机分为模型组和活血解毒方高、中、低剂量组(15.4,7.70,3.85 g.kg-1)及导升明组(0.167 g.kg-1),ig给药,20周后处死,取血清检测AngⅡ和ET-1的含量。摘除眼球应用免疫组织化学标记抗生蛋白连菌素法(LSAB)法检测大鼠视网膜全层ET-1的表达。取大鼠视网膜组织,采用实时聚合酶链反应Real-time PCR检测ET-1 mRNA的表达。结果:糖尿病模型组大鼠血清AngⅡ和ET-1含量分别为(417.95±156.11),(330.12±81.59)ng.L-1,比正常组升高(P<0.01)。糖尿病模型组大鼠视网膜LSAB法标记染色病理切片中ET-1蛋白的表达升高,积分吸光度(IA)为(53.45±15.67),与正常组相比(12.76±3.27)显著升高(P<0.01),活血解毒方各剂量组及导升明组与模型组相比显著降低(P<0.01)。模型组ET-1 mRNA的表达显著高于正常组,活血解毒方各剂量组的表达明显低于模型组,与模型组相比有显著性差异。结论:活血解毒方可能通过降低视网膜ET-1的表达,延缓糖尿病大鼠视网膜病变的发展。
Objective： To observe the effect of Huoxue Jiedu formula on angiotensin Ⅱ （Ang Ⅱ ） and endothelin-1 （ET-1） in retina of diabetic rats. Method： A single intraperitoneal injection of streptozotocin （65 mg-kg-1） was used to induce diabetic rats. Model rats were randomly divided into diabetes mellitus （DM） group, Huoxue Jiedu formula groups （15.4, 7.70, 3.85 g .kg-1 ） and Doxium group （0. 167 g -kg-1 ）. The normal group and model group were given normal water by intragastric administration. All rats were killed after 20 weeks. The serum Ang [I and ET-1 levels were measured. Immunological histochemistry assay was used to observe the express of ET-1. The expressive abundance of ET-lmRNA in rat＇s retina were detected by real-time quantitative PCR. Result： The levels of Ang II and ET-1 in serum of model group were （417.95 -＋ 156. 11 ） , （330. 12 ＋ 81.59） ng L-1, which was higher than control group. The retinal ET-1 protein expression and ET-lmRNA were significantly higher in DM rats than in control group （P 〈 O. 01 ）. The levels of ET-1 in serum of Huoxue Jiedu formula groups were lower than those in model group （P 〈 0.01）. Compared with the model group, the expression of ET-1 in Huoxue Jiedu formula groups depressed evidently （P 〈0.01） and the expression of ET-lmRNA were reduced than those in model groups （P 〈 0.01 ）. Conclusion： Huoxue Jiedu formula .medicine can reduce the expression of ET-1 in retina of diabetic rats.
出处
《中国实验方剂学杂志》
CAS
北大核心
2012年第20期169-172,共4页
Chinese Journal of Experimental Traditional Medical Formulae
基金
国家重大新药创制课题(2009ZX09103-320)
科技部国际科技合作项目(2008DFA30610)
作者简介
姚青，博士研究生在读，讲师，从事中药药理学研究，Tel：18910378726，E-mail：yaoqlng726@163．com
[通讯作者]王伟，博士，教授，博士生导师，从事中药药理学研究，Tel：010＆4286283，E．mail：wangwei26960@126．com
